Core Insights - The white paper by BullFrog AI discusses the importance of data harmonization in biopharma, emphasizing how the company's bfPREP technology transforms noisy biomedical data into standardized, AI-ready datasets [1][2][3] Group 1: Data Harmonization - BullFrog AI's bfPREP technology addresses the challenges of fragmented and unstructured biomedical data, enabling the creation of clean, analysis-ready datasets [2][3] - The white paper outlines a practical framework for data harmonization based on three pillars: engineering clinically meaningful derived features, producing reliable categorical variables and harmonized schemas, and transforming unstructured clinical documents into analysis-ready tables [2] Group 2: AI and Machine Learning Value - The true value of AI and machine learning in life sciences is realized through data harmonization, which allows teams to focus on interpreting results and making decisions rather than data wrangling [3] - BullFrog AI aims to reduce clinical trial failure rates by providing reliable datasets that enhance the efficiency of drug development processes [3][4]

Core Insights - The company's bfLEAP® platform has demonstrated a significant increase in mean survival rates for pancreatic cancer patients, showing an almost threefold improvement from control to treatment arms [1][3][4] - Data from the pancreatic cancer trial will be presented at the 2026 ASCO GI symposium and subsequently published in the Journal of Clinical Oncology [2] Company Overview - BullFrog AI Holdings, Inc. utilizes artificial intelligence and machine learning to transform complex biomedical data into actionable insights, aiming to enhance drug discovery and development [6] - The company collaborates with leading research institutions to apply causal AI and its proprietary platforms, bfLEAP® and bfPREP™, to analyze complex clinical datasets [6] Research Findings - The study focused on glufosfamide, an investigational chemotherapeutic agent, and identified key biomarkers that contributed to the increased survival rates in pancreatic cancer patients [3][4] - The research concluded that data-driven clustering approaches can effectively refine patient stratification and guide personalized treatment strategies [4]

Core Insights - BullFrog AI Holdings, Inc. has made significant progress in 2025, positioning itself for transformative growth in 2026 through advancements in technology, commercial execution, and external validation [2][3][15] Commercial Development - The company is engaged in advanced discussions with large pharmaceutical organizations for potential commercial transactions, including out-licensing and discovery research collaborations, indicating a growing recognition of its platform's value [4][15] - A commercial collaboration with Sygnature Discovery was established in Q2 2025, expected to generate significant revenue through 2028, enhancing BullFrog AI's commercial reach [5][15] - Internal sales and marketing efforts have been expanded to support clinical trial optimization solutions, leveraging successful use cases in oncology and neuroscience to drive engagement [6][15] Technological Advancements - The evolution of BullFrog AI's technology into a modular, enterprise-grade solutions stack supports broader commercial adoption, allowing clients to deploy targeted solution modules [7][8] - The launch of bfPREP™, an AI-powered data preparation tool, addresses challenges in transforming unstructured data into AI-ready datasets, significantly reducing preparation timelines [12][13] Scientific Validation - A collaboration with Eleison Pharmaceuticals represents a significant real-world deployment of BullFrog AI's platforms in a late-stage oncology program, demonstrating the ability to deliver actionable insights in clinical development [9][10] - Insights from this collaboration will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium, which is expected to enhance commercial engagement opportunities [11][15] Financial Strategy - The company maintains a disciplined approach to capital allocation with an annual burn of approximately $6.2 million, creating substantial operating leverage as commercial opportunities convert [14][15] - Additional financing flexibility has been established, including a $10 million equity line of credit, to support execution as opportunities advance [14] Future Outlook - BullFrog AI anticipates several catalysts in 2026, including continued commercialization through Sygnature Discovery, expanding engagement around bfPREP™, and executing contracts with large pharmaceutical companies [16][17] - The foundation built in 2025 is expected to translate into meaningful commercial outcomes, reinforcing the company's role as a trusted partner in data-driven drug development [17]

Core Insights - BullFrog AI Holdings, Inc. has published a whitepaper titled "AI in Bioinformatics: Turning Complex Data into Actionable Insights with BullFrog Data Networks," highlighting its technology's role in addressing AI challenges in drug discovery and development [1][5] - The company emphasizes that the life sciences industry is at a critical juncture where data interpretation is more crucial than data abundance, positioning itself as a leader in causal AI and bioinformatics [1][4] Bioinformatics Challenges - The whitepaper identifies three major pitfalls in modern bioinformatics: the compositional data trap, the mirage of feature importance, and the overreach of generative AI, which contribute to high clinical development failure rates and significant R&D investment waste [2] Technological Solutions - BullFrog AI's bfLEAP platform utilizes causal inference modeling and probabilistic validation methods to overcome bioinformatics challenges, enabling reproducible insights across various datasets, including genomics and clinical data [3] Industry Positioning - The publication reinforces BullFrog AI's role in bridging the gap between data availability and actionable biological understanding, with a modular and scalable approach that combines bfPREP™, bfLEAP, and BullFrog Data Networks [4] Impact on Drug Development - The whitepaper serves as a roadmap for how AI can deliver measurable impacts in the pharmaceutical industry, demonstrating that BullFrog AI's frameworks can enhance efficiency, predictability, and profitability in drug development [5]

Revenue Recognition - The company recognized revenue of approximately $65,000 from its first commercial service contract in Q3 2023 and $83,000 and $117,000 in revenue for the three and nine months ended September 30, 2025, respectively, from a collaboration agreement with Eleison Pharmaceuticals[109]. - The company recognized a cost of revenue of approximately $68,000 for the three months ended September 30, 2025, related to its collaboration with Eleison[113]. - Collaboration revenue recognized for the nine months ended September 30, 2025 was approximately $117,000, with a cost of revenue of approximately $95,000, entirely related to the collaboration with Eleison[118]. Financial Position - As of September 30, 2025, the company has a cash balance of approximately $2.1 million, which is insufficient to fund planned operations for at least one year beyond the filing date, raising substantial doubt about its ability to continue as a going concern[104]. - As of September 30, 2025, the company's cash and cash equivalents were insufficient to fund planned operations for at least one year, raising substantial doubt about its ability to continue as a going concern[127]. - The company has an accumulated deficit of approximately $21.8 million as of September 30, 2025, funded primarily through the sale of common stock, warrants, and debt[123]. Operating Performance - The company has incurred negative cash flows from operations and has operated at a net loss since inception, requiring additional capital to execute its strategy[105]. - Net cash used in operating activities for the nine months ended September 30, 2025 was $(4,337,270), slightly improved from $(4,338,214) in the same period of 2024[129]. - Total operating expenses for the three months ended September 30, 2025 decreased to $1,585,053 from $1,819,941 in the same period of 2024, a reduction of $234,888[114]. Research and Development - Research and development costs are expected to become significant as the company conducts preclinical research and development activities for its licensed drug development programs[111]. - Research and development expenses for the three months ended September 30, 2025 decreased to $345,992 from $566,584 in the same period of 2024, a reduction of $220,592[114]. Capital and Financing - The company plans to secure additional capital through revenues from licensing agreements and collaborative arrangements, as well as potential equity or debt transactions[105]. - The company completed its IPO in February 2023, receiving net proceeds of approximately $5.7 million from a public offering in February 2024 and $2.7 million from a registered direct offering in October 2024[104]. - The company entered into a purchase agreement with Lincoln Park for up to $10 million of common stock, with no shares sold under this facility during the nine months ended September 30, 2025[126]. - Net cash provided by financing activities for the nine months ended September 30, 2025 decreased to $996,999 from $5,952,472 in the same period of 2024, a decrease of $4,955,473[132]. Licensing and Collaborations - The company entered into a new license agreement with JHU-APL in July 2022, entitling JHU-APL to 8% of net sales for services provided to other parties and 3% for internally developed drug projects[97]. - The company has signed exclusive worldwide license agreements for cancer drugs targeting glioblastoma and hepatocellular carcinoma, enhancing its drug development portfolio[101]. Interest Income - Interest income for the nine months ended September 30, 2025 was approximately $83,000, down from approximately $205,000 in the same period of 2024, primarily due to a decrease in average cash balance[122]. General and Administrative Expenses - General and administrative expenses for the three months ended September 30, 2025 decreased to $1,239,061 from $1,253,357 in the same period of 2024, a reduction of $14,296[116].

Core Insights - BullFrog AI Holdings, Inc. will present a technical talk on "Human-in-the-Loop Agent Workflows with bfPREP™" at the AI Drug Discovery & Development Summit 2025, highlighting its AI-driven drug development capabilities [1][2] Company Overview - BullFrog AI is a technology-enabled drug development company that utilizes artificial intelligence and machine learning to enhance the development of pharmaceuticals and biologics [1][5] - The company aims to streamline drug discovery and reduce clinical trial failure rates through collaborations with leading research institutions and its proprietary bfLEAP platform [5] Product Insights - The bfPREP™ module is designed for data cleansing and preparation, automating the detection, correction, and standardization of clinical, omics, and real-world data, thus converting fragmented information into analysis-ready datasets [3] - The technology emphasizes human-in-the-loop validation to ensure data integrity and reproducibility, making it essential for improving drug development efficiency [3] Event Details - The AI Drug Discovery & Development Summit 2025 will take place from November 18–20, 2025, in Boston, Massachusetts, featuring over 500 attendees and 100 expert speakers [4]

Core Insights - BullFrog AI Holdings, Inc. announced the acceptance of an abstract for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, highlighting the company's advancements in AI-driven precision oncology [1][2] - The study focuses on identifying patient subtypes that may respond better to glufosfamide, an investigational drug for pancreatic cancer, utilizing BullFrog AI's proprietary platforms [3][4] Company Overview - BullFrog AI is a technology-enabled drug development company that employs artificial intelligence and machine learning to enhance pharmaceutical and biologic development [1][5] - The company collaborates with leading research institutions to analyze complex biological data, aiming to improve drug discovery and reduce clinical trial failure rates [5] Collaboration and Research - The research was co-authored by experts from Moffitt Cancer Center and Eleison Pharmaceuticals, emphasizing the collaborative nature of the study [3] - The abstract titled "Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma" will be presented during the symposium and published in the Journal of Clinical Oncology [2][4] Industry Impact - The acceptance of the abstract by ASCO signifies the increasing recognition of AI's transformative potential in oncology research [4] - The study aims to provide insights that could lead to more precise and effective treatment strategies for challenging cancers like pancreatic adenocarcinoma [4]

Core Insights - BullFrog AI Holdings, Inc. is hosting a webinar on October 30, 2025, to discuss its advancements in drug development using AI and machine learning [1] - The event will feature insights from the founder and CEO, Vin Singh, highlighting the company's innovative AI-driven platforms and recent product launches [2] Company Overview - BullFrog AI focuses on transforming drug discovery and development through its scalable AI-driven platforms, including the BullFrog Data Networks™ Solutions Library and the bfLEAP™ causal AI engine [2] - The newly launched bfPREP™ module automates data cleansing and standardization, providing a flexible toolkit for drug development [2] - The company has strategic global collaborations, notably with CRO Sygnature Discovery, aimed at expanding commercial reach and driving revenue growth [2] Event Details - The webinar will include a live Q&A session following the presentation, allowing attendees to engage directly with the company's leadership [3] - Registration for the free webinar is available online, with options for pre-submitting questions [4]

As filed with the Securities and Exchange Commission on October 10, 2025. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BULLFROG AI HOLDINGS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation) (Commission File Number) Nevada 001-41600 84-4786155 (I.R.S. Employer Identification No.) 325 Ellington Blvd, Unit 317 Gaithersburg, MD 2087 ...

Core Insights - Several biotech and healthcare stocks experienced significant after-hours gains on October 1, driven by technical momentum and recent clinical updates rather than new disclosures [1] Company Summaries - Zhongchao Inc. (ZCMD) saw a 14.04% increase in after-hours trading, rising to $1.30 from $1.14, despite no new filings or press releases [2] - AbCellera Biologics Inc. (ABCL) rose 11.41% in after-hours trading, closing at $6.64, following an 18.49% gain during the regular session, attributed to recent clinical trial progress [3][4] - Vor Biopharma Inc. (VOR) surged 9.53% in after-hours trading, recovering from a 19.42% drop during the regular session, with no new updates since a recent announcement regarding clinical data presentation [5] - Incannex Healthcare Inc. (IXHL) gained 6.48% in after-hours trading, partially recovering from a 6.94% drop, with the latest update showing positive Phase 2 trial results for PSX-001 [6] - Ovid Therapeutics Inc. (OVID) shares rose 8.03% in after-hours trading, building on a 5.38% gain during the regular session, with recent earnings report indicating a narrower net loss and higher revenue [7] - Bullfrog AI Holdings Inc. (BFRG) advanced 3.44% in after-hours trading, following a 3.57% rise during the regular session, after announcing an expansion of its sales and marketing team [8]